Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
BA heads into its October 21 earnings print with options traders now firmly leaning bullish, even as the stock trades nearly $84 below the Street's consensus price target.
The clearest shift since last week's note is in the put/call ratio. It has dropped to 0.766, more than two standard deviations below its 20-day average of 0.849, and is now within reach of its 52-week low of 0.724. That is an unusually strong tilt toward calls relative to recent history, and it has continued moving in the same direction all week. The stock closed Tuesday at $189.82, up 1.1% on the week after a 1.5% dip on Tuesday itself, and is still down more than 10% over the past month. The options market and the price chart are telling different stories.
Short positioning remains a non-event. Short interest is 1.94% of free float, up about 3.5% on the week but essentially unchanged from the levels flagged in the previous note. More telling is the borrow picture: availability is running at roughly 5,320% of shares short, meaning the lending pool holds more than 53 shares for every one currently borrowed. Cost to borrow ticked up 36% on the week to 0.27%, but that follows a 44% drop over the prior month, and the absolute level is negligible. The ORTEX short score has barely moved in ten days, sitting at 31.2. There is no short-side pressure building here.
The Street remains broadly constructive, though the gap between the mean price target of $273 and the current price of $190 is as much a reflection of execution risk as it is of upside conviction. The most recent analyst action came from Jefferies, which on September 21 cut its target from $295 to $265 while keeping its Buy rating, the same direction taken by RBC Capital after the July quarter results. BofA Securities reiterated Buy at $270 in mid-September. The bull case rests on the record $715 billion commercial backlog, the 737 ramp toward 47 units per month, and Q2 free cash flow turning positive at $631 million. The bear case is harder to dismiss: LTM NOPAT is still a $4.52 billion loss, the $280 million Air Force One charge showed program risk is not behind the company, and negative return on capital means the recovery story is not yet in the financials. Factor scores offer a partial bridge: EPS momentum over both 30 and 90 days ranks in the 98th percentile, and EPS surprise is at the 93rd percentile, suggesting the revision cycle has been moving in the right direction even if absolute profitability remains impaired.
The institutional register shows broad, stable ownership with no activist presence. BlackRock holds 7.7% as the largest single holder, and FMR added roughly 1.1 million shares through September. Capital Research and Management added nearly 10 million shares in the same period, a notable build at current prices. No 13D activist is on the register, and all major 13G filers are passive. The dividend was suspended in 2020 and has not been reinstated; the dividend history in the data is stale and carries no current relevance.
The last two quarterly prints produced modest immediate moves: a near-flat day-one reaction in July followed by an 8% five-day gain, and a 1.2% day-one gain in the most recent quarter with a 12% five-day rally. Both episodes saw the stock drift higher over the week following results, even when the initial reaction was subdued. With earnings now 14 days away, the question is whether the call-heavy options positioning and the improving EPS revision trend are enough to offset the persistent gap between the company's reported financials and what the target prices assume.
See the live data behind this article on ORTEX.
Open BA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
